18-MC, tabernanthalog, and derivatives
Analogs
Analogs are not interchangeable with Iboga, Ibogaine, or Noribogaine. Each derivative needs its own molecule-level record, evidence type, sponsor or lab context, safety claims, and clinical-development status.
Key Points
- 18-MC, tabernanthalog, and related derivatives should be tracked by molecule, not treated as Ibogaine synonyms.
- Preclinical promise, patent language, investor material, and human clinical evidence are different source types.
- Claims that an analog is non-hallucinogenic, non-cardiogenic, or safer require source-specific evidence.
- A derivative's legal, safety, and cultural meaning can differ from Iboga and Ibogaine.
Why Analogs Need Their Own Lane
Analog programs often try to keep or isolate a desired biological effect while changing other features of the parent compound. That makes the source trail more complex, not simpler.
IbogaBase tracks analogs separately so readers do not mistake a preclinical derivative, a patent claim, or an investor presentation for evidence about Ibogaine itself.
Analog Claim Checklist
- Which molecule is being discussed: 18-MC, tabernanthalog, oxa-Ibogaine, another derivative, or a vague class label?
- What is the evidence type: preclinical paper, patent, company release, registered trial, conference claim, or peer-reviewed human result?
- Who is the sponsor, lab, or rights holder, and are conflicts or commercial incentives visible?
- Does the claim specify condition, endpoint, safety signal, comparator, and development status?
Sources
Continue reading
Reader Boundary
Educational reference material only; not medical advice, legal advice, dosing instruction, provider referral, or emergency guidance. Emergency, treatment, and legal decisions belong with qualified professionals and local emergency systems.